HomeFocus → FDA approves novel preventive treatment for migraine

FDA approves novel preventive treatment for migraine Print E-mail
Written by   
Thursday, 17 May 2018 00:00
The U.S. Food and Drug Administration today <5.17.18> approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.

"Aimovig provides patients with a novel option for reducing the number of days with migraine," said Eric Bastings, MD, Deputy Director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research.
Read the Press Release

Website design, development, and hosting provided by